S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
Log in

NASDAQ:ADIL - Adial Pharmaceuticals Stock Price, Forecast & News

$1.20
-0.10 (-7.69 %)
(As of 04/1/2020 04:00 PM ET)
Today's Range
$1.05
Now: $1.20
$1.28
50-Day Range
$1.05
MA: $1.45
$1.78
52-Week Range
$1.00
Now: $1.20
$3.47
Volume46,576 shs
Average Volume67,998 shs
Market Capitalization$12.58 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADIL
CUSIPN/A
Phone434-422-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.69 per share

Profitability

Net Income$-8,590,000.00

Miscellaneous

Employees3
Market Cap$12.58 million
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive ADIL News and Ratings via Email

Sign-up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.


Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

How has Adial Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ADIL shares have decreased by 11.1% and is now trading at $1.20. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Adial Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adial Pharmaceuticals.

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Adial Pharmaceuticals.

What price target have analysts set for ADIL?

2 brokers have issued 1 year price objectives for Adial Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Adial Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View analysts' price targets for Adial Pharmaceuticals.

Has Adial Pharmaceuticals been receiving favorable news coverage?

News coverage about ADIL stock has been trending very negative on Wednesday, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adial Pharmaceuticals earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAdial Pharmaceuticals.

Are investors shorting Adial Pharmaceuticals?

Adial Pharmaceuticals saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 40,900 shares, an increase of 42.0% from the February 27th total of 28,800 shares. Based on an average trading volume of 63,200 shares, the short-interest ratio is currently 0.6 days. Currently, 0.6% of the shares of the company are sold short. View Adial Pharmaceuticals' Current Options Chain.

Who are some of Adial Pharmaceuticals' key competitors?

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Tandem Diabetes Care (TNDM), Altria Group (MO), Adobe (ADBE), Inovio Pharmaceuticals (INO), New Age Beverages (NBEV), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC) and Pfizer (PFE).

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the following people:
  • Mr. William B. Stilley III, M.B.A., MBA, CEO, Pres, Sec., Treasurer & Director (Age 51)
  • Prof. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 59)
  • Mr. Joseph M. Truluck M.B.A., MBA, CFO & COO (Age 41)
  • Ms. Monika Z. Rogozinska, Chief Devel. Officer
  • Mr. Alex Lugovoy, Head of Strategy

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $1.20.

How big of a company is Adial Pharmaceuticals?

Adial Pharmaceuticals has a market capitalization of $12.58 million. Adial Pharmaceuticals employs 3 workers across the globe. View additional information about Adial Pharmaceuticals.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is http://www.adialpharma.com/.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1001 RESEARCH PARK BLVD. SUITE 100, CHARLOTTESVILLE VA, 22911. The company can be reached via phone at 434-422-9800 or via email at [email protected]


MarketBeat Community Rating for Adial Pharmaceuticals (NASDAQ ADIL)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: Stocks Increasing Dividends

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel